Mobile applications on app stores for deprescribing: A scoping review.

Abstract

Deprescribing is an evidence-based intervention to reduce potentially inappropriate medication use. Yet its implementation faces barriers including inadequate resources, training and time. Mobile applications (apps) on app stores could address some barriers by offering educational content and interactive features for medication assessment and deprescribing guidance. A scoping review was undertaken to examine existing deprescribing apps, identifying features including interactive and artificial intelligence (AI) elements. A comprehensive search was conducted in August 2023 to identify mobile apps with deprescribing content within the Apple and Google Play Stores. The apps found were screened for inclusion, and data on their features were extracted. Quality assessment was undertaken using the Mobile App Rating Scale. Six deprescribing-related apps were identified: the American Geriatrics Society Beers Criteria 2023, Dementia Training Australia Medications, Evidence-Based Medicine Guide, Information Assessment Method Medical Guidelines, MedGPT-Medical AI App, and Polypharmacy: Manage Medicines. These apps focused primarily on educating both patients/carers and healthcare professionals about deprescribing. Amongst them, two apps included interactive features, with one incorporating AI technology. While these features allowed for search queries and input of patient-level details, the apps provided limited personalised deprescribing advice. In terms of quality, the apps scored highly on functionality and information, and poorly on engagement and aesthetics. This review found deprescribing apps, despite being educational, have limitations in personalization and user engagement. Future research should prioritize evaluating their feasibility and user experience in clinical settings, and further explore how AI and interactivity could enhance the usefulness of these apps for deprescribing practices.